• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Capricor Therapeutics (CAPR) Falls On FDA Doubts, Where Does Fair Value Sit?

    Simply Wall St·07/29/2026 15:12:33
    Listen to the news

    Capricor Therapeutics (CAPR) is under intense scrutiny after FDA briefing documents questioned the efficacy and statistical analysis of Deramiocel for Duchenne muscular dystrophy, triggering a sharp share price drop and multiple law firm investigations.

    See our latest analysis for Capricor Therapeutics.

    The latest FDA briefing has sharply changed sentiment around Capricor Therapeutics, with the share price falling 66.8% over the past week and 76.8% year to date. At the same time, the 3 year total shareholder return of 43.1% and 5 year total shareholder return of 47.6% show that long term holders have still seen gains despite the recent repricing of regulatory risk.

    If this kind of regulatory shock has you reassessing your watchlist, it can help to compare with other healthcare names using a focused screener for 40 healthcare AI stocks.

    After a drop that leaves Capricor Therapeutics trading at US$6.57, while analyst and intrinsic value estimates sit far higher, the real focus is where fair value now lies within such a wide spread.

    Most Popular Narrative: 88.7% Undervalued

    Capricor Therapeutics last closed at $6.57 while the most followed narrative sets fair value at $58. That gap reflects a very different view of what Deramiocel and the exosome platform could be worth if key assumptions play out.

    The most compelling reason to look at Capricor right now is that Deramiocel is just the tip of the iceberg. An FDA approval functionally validates the therapeutic viability of the company's underlying exosome platform. Capricor is already leveraging this momentum to develop StealthX, a next-generation engineered exosome platform capable of carrying specific tissue-targeted genetic payloads, spanning from vaccines to oncological therapeutics.

    Read the complete narrative.

    This narrative, shared by AnimalDoctorKwon, leans heavily on high projected revenue growth, a shift from losses to profitability, and a premium future earnings multiple that together help justify a fair value nearly nine times above the last close. It rests on specific assumptions about how fast exosome based therapies could scale, how margins might evolve, and how investors might value a successful platform company.

    Result: Fair Value of $58 (UNDERVALUED)

    Have a read of the narrative in full and understand what's behind the forecasts.

    However, this Capricor Therapeutics narrative could be knocked off course if the FDA maintains concerns around Deramiocel, or if the NS Pharma dispute escalates.

    Find out about the key risks to this Capricor Therapeutics narrative.

    Next Steps

    Given the split between recent share price pressure and past gains for Capricor Therapeutics, it makes sense to move fast and check the data yourself. To balance the concerns and the potential upside, start with a clear view of the 2 key rewards and 3 important warning signs.

    Looking for more investment ideas beyond Capricor Therapeutics?

    If Capricor Therapeutics has you rethinking your next move, do not stop here. Use focused stock screeners to quickly spot ideas that better match your goals.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.